These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 8033091)

  • 41. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride.
    Morimoto S; Matsuura I; Shono Y; Horiuchi T; Nakajima Y; Miyabe T; Hachino Y; Hasegawa K; Matsuyama K; Fujita Y; Tabuse K
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1135-40. PubMed ID: 19620803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
    Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
    Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
    Rivory LP; Robert J
    Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
    Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
    Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.
    Balram C; Zhou QY; Cheung YB; Lee EJ
    Drug Metabol Drug Interact; 2002; 19(2):137-48. PubMed ID: 12751911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
    Araki E; Ishikawa M; Iigo M; Koide T; Itabashi M; Hoshi A
    Jpn J Cancer Res; 1993 Jun; 84(6):697-702. PubMed ID: 8340259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
    Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
    J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
    Kurita A; Kaneda N
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
    Tamura T; Yasutake K; Nishisaki H; Nakashima T; Horita K; Hirohata S; Ishii A; Hamano K; Aoyama N; Shirasaka D; Kamigaki T; Kasuga M
    Oncology; 2004; 67(5-6):327-37. PubMed ID: 15713987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
    Chowbay B; Sharma A; Zhou QY; Cheung YB; Lee EJ
    Oncol Rep; 2003; 10(3):745-51. PubMed ID: 12684653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel agents that potentially inhibit irinotecan-induced diarrhea.
    Yang X; Hu Z; Chan SY; Chan E; Goh BC; Duan W; Zhou S
    Curr Med Chem; 2005; 12(11):1343-58. PubMed ID: 15975002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
    Kaneda N; Nagata H; Furuta T; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
    Yamauchi T; Amaya N; Yoshio N; Yoshida A; Tsutani H; Ueda T
    Int J Hematol; 1999 Apr; 69(3):165-9. PubMed ID: 10222654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
    Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
    Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.